Investors lost big as Alzheimer’s R&D went over the cliff in 2019. Will they ever come back?
Neurotrope this week joined the long line of biopharma companies that have been mauled by clinical failure for Alzheimer’s drugs. But their crushed shares ($NTRP down from more than $8 in June to penny stock range today) represented just a tiny drop in the bucket of red ink that has drained from players which have pursued the greatest of all Holy Grails in drug R&D. Decades of defeat, headlined by the likes of solanezumab at Eli Lilly stretching to the most recent snafu with Biogen’s aducanumab, have forced a slew of players to change course on their R&D strategy — or just leave it in limbo.